A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young adults. The study will also look at the safety of the new vaccine as well as how it is tolerated.
Inclusion Criteria:
Exclusion Criteria:
Tempe, Arizona 85282, United States
Tempe, Arizona 85283, United States
Hollyood, Florida 33024, United States
Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
Sainte-Foy, Québec, Quebec G1W 4R4, Canada
Balenya, Barcelona 08550, Spain